Sat, 14 Nov 2026
11:59:21 pm
Rudransh Sangwan
Published at: October 30, 2026, 4:06 AM
Synopsis
Bliss GVS Pharma Q2 FY27 results show revenue rising 37.3% to ₹261.13 crore, EBITDA jumping 161.4% and net profit increasing 196%.

Bliss GVS Pharma reported a 37.3% year-on-year increase in standalone revenue to ₹261.13 crore in Q2 FY27. EBITDA surged 161.4% to ₹8.06 crore, while the EBITDA margin expanded to 25.71% from 12.58% a year earlier.
| Financial Metric | Q2 FY27 | Q2 FY26 | Growth |
|---|---|---|---|
| Revenue | ₹261.13 crore | ₹190.23 crore | +37.3% |
| EBITDA | ₹8.06 crore | ₹3.08 crore | +161.4% |
| EBITDA Margin | 25.71% | 12.58% | Improved |
| Net Profit | ₹73.57 crore | ₹24.79 crore | +196% |
Standalone net profit rose 196% to ₹73.57 crore, supported partly by a ₹41.09 crore exceptional gain from reversing an impairment provision on investments in its wholly owned subsidiary, Bliss GVS International Pte. Ltd.
Even excluding the exceptional item, profit before tax and exceptional items increased 71.2% year-on-year to ₹57.28 crore, indicating improvement in underlying performance.
Anupam Rasayan India Limited acquired a 50.07% stake in Bliss GVS Pharma during the quarter and became its holding company and promoter on September 28, 2026.
| Period | Return |
|---|---|
| 1 day | -4.99% |
| 5 days | +5.94% |
| 1 month | -4.22% |
| 6 months | +154.68% |
| 1 year | +347.81% |
| 5 years | +514.53% |
Key takeaway: Bliss GVS Pharma recorded strong revenue and EBITDA growth in Q2 FY27, although its sharp standalone net profit increase was partly driven by a one-time impairment reversal.

Financial journalist specializing in market analysis, stock research, and investment trends. Dedicated to providing accurate, timely insights for informed decision-making.
Credentials: Experienced financial journalist with expertise in equity markets and economic analysis
The information provided in this article is for educational and informational purposes only and should not be construed as financial, investment, or legal advice. welomoney does not provide personalized investment recommendations.
For detailed terms and conditions, please read our Disclaimer and Terms of Service.

Kellton Tech Q2FY27 results: Revenue grows 6.5% to ₹3,206 million. Check net profit, EBITDA margins, H1 performance and the new GCC joint venture.

Swaraj Suiting Q2FY27 results: Net profit rises 94% to ₹1,728.82 lakh as revenue jumps 72%. Check H1FY27 earnings, cash flow, borrowings and...

Super Tannery Q2FY27 results: Standalone net profit rises 128% to ₹257.58 lakh, while revenue grows 28.17%. Check consolidated results and cash flow.

Parvati Sweetners Q2FY27 results show revenue of ₹1,373.34 lakh and a narrower net loss of ₹203.05 lakh.

Jindal Poly Films Q2FY27 results: Standalone net loss widens to ₹349.98 crore after a ₹292 crore subsidiary loan provision.